Arcutis Biotherapeutics, Inc. Form 4 Filings

Arcutis Biotherapeutics, Inc. (ARQT) director Terrie Curran reported an option exercise-and-sale sequence. Curran exercised a stock option for 1,072 shares of common stock at an exercise price of $7.51 per share, then sold 1,072 shares of common stock at a weighted average sale price of $26.0376 per share in multiple trades between $26.00 and $26.2228. After the derivative transaction, Curran held 11,148 stock options directly, with the option described as fully vested and expiring on May 31, 2033.

Arcutis Biotherapeutics, Inc. (ARQT) reported that EVP and Chief Medical Officer Patrick Burnett sold 1,697 shares of common stock on 2026-08-19 at $27.00 per share. A footnote states the sale was made to cover tax withholding obligations related to vesting Restricted Stock Units, leaving him with 117,592 shares directly held.

Arcutis Biotherapeutics, Inc. (ARQT) director Howard G. Welgus reported option exercises and a share sale. He exercised fully vested stock options covering 4,096 shares of common stock at exercise prices of $6.5223, $7.51, and $8.63 per share, acquiring the same number of common shares. On the same date, he sold 4,730 shares of common stock at a weighted average price of $26.1807 per share, in multiple trades between $26.10 and $26.25, pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2026 with a plan end date of June 15, 2027.

Arcutis Biotherapeutics EVP and Chief Medical Officer Patrick Burnett reported an exercise-and-sell transaction in company stock. On August 11 and 12, 2026, he exercised stock options for a total of 15,000 shares of common stock at an exercise price of $3.64 per share and sold the same 15,000 shares in open-market transactions at weighted average prices of $26.52 and $26.08, respectively. The filing does not state his remaining share or option holdings.

Arcutis Biotherapeutics EVP and Chief Medical Officer Patrick Burnett reported selling 955 shares of common stock on 2026-08-03 at a weighted-average price of $26.1168 per share, in multiple trades between $25.72 and $26.69. Footnotes state the sale was solely to cover tax withholding obligations arising from vesting Restricted Stock Units and was effected pursuant to a Rule 10b5-1 trading plan. After this transaction, Burnett directly owns 119,289 shares of Arcutis common stock.

Arcutis Biotherapeutics executive Masaru Matsuda, EVP and Chief Legal Officer, reported selling 1,230 shares of common stock on August 3, 2026 at a weighted average price of $26.1168 per share under a Rule 10b5-1 trading plan. The sale represents shares sold to cover tax withholding obligations arising from the vesting of Restricted Stock Units, with trade prices ranging from $25.72 to $26.69. Following this transaction, Matsuda directly holds 126,171 shares, including 712 shares acquired through the company’s Employee Stock Purchase Plan.

Arcutis Biotherapeutics President and CEO Todd Watanabe sold 4375.0000 shares of common stock on August 3, 2026 at a weighted average price of $26.1168 (with individual prices from $25.72 to $26.69) to cover tax withholding obligations arising from the vesting of Restricted Stock Units, in a transaction reported under a Rule 10b5-1 trading plan. After this sale he directly held 717203.0000 shares, including 823 acquired through the Employee Stock Purchase Plan, and additional shares are held indirectly through trusts and Watanabe Ventures, LLC, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.

Arcutis Biotherapeutics director Christopher Peetz reported equity awards and holdings. On July 15, 2026 he received 4,315 RSUs, each convertible into one share upon vesting on the earlier of June 5, 2027 or immediately before the next annual stockholder meeting, subject to continued service.

He also received stock options for 21,486 and 13,010 shares at an exercise price of $27.78 per share, vesting over time as described and expiring July 15, 2036. An additional 187,500 shares are held indirectly by The Peetz Family Trust, for which he disclaims beneficial ownership beyond his pecuniary interest.

Arcutis Biotherapeutics director Howard G. Welgus reported multiple Common Stock transactions on July 15, 2026. He sold 4,730 shares at $26.91 per share and exercised stock options to acquire 2,255, 1,019 and 822 shares at exercise prices of $8.63, $7.51 and $6.5223, respectively. Following these trades, he directly owned 37,109 shares of Common Stock. All transactions were effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, with a plan end date of June 15, 2027.

Arcutis Biotherapeutics director Sue-Jean Lin sold 4,946 shares of common stock in an open-market transaction at a weighted average price of $24.38 per share. After the sale, she directly holds 27,567 shares. The trade was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 4, 2025.

Arcutis Biotherapeutics director Howard G. Welgus reported option exercises and share sales in the company’s stock. On June 15, 2026, he exercised stock options to acquire a total of 4,096 shares of common stock at exercise prices between $6.5223 and $8.63 per share.

On the same day and on June 17, 2026, he sold a total of 4,731 shares of common stock in open-market transactions at weighted average prices of $24.4093 and $25.67 per share, respectively. The filing states these trades were made under a pre-arranged Rule 10b5-1 trading plan. After these transactions, Welgus directly owned 37,743 shares of Arcutis common stock.

Arcutis Biotherapeutics director Patrick J. Heron filed an amended insider report that corrects his indirect share holdings. A prior Form 4 understated the number of common shares indirectly held through Frazier Life Sciences X, L.P. by 2,646 shares due to a scrivener's error. After this correction, 27,448 shares of common stock are reported as indirectly held. These shares are owned of record by Frazier Life Sciences X, L.P., whose general partners are affiliated entities where Heron is one of two managing members. He disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

Arcutis Biotherapeutics director Patrick J. Heron reported new equity awards. He received 5,778 Restricted Stock Units in connection with his service as a non-employee director at the 2026 annual stockholder meeting. Each RSU converts into one share of common stock upon vesting.

The RSUs vest 100% on the earlier of the first anniversary of the June 5, 2026 grant date or immediately before the next annual meeting, subject to continued service, and settlement has been deferred under a prior deferral election. Heron also received a stock option for 16,667 shares at an exercise price of $21.23 per share, vesting on the same schedule and expiring on June 5, 2036.

Following these awards, he holds 32,213 shares directly, in addition to indirect interests in shares held by The Heron Living Trust and several Frazier Life Sciences entities, for which he disclaims beneficial ownership beyond his pecuniary interest.

Arcutis Biotherapeutics director Sue-Jean Lin reported equity awards tied to board service. She received 5,778 Restricted Stock Units as of the company’s 2026 annual stockholder meeting, bringing her direct common stock holdings to 32,513 shares after the award.

Each RSU converts into one share of common stock upon vesting, which occurs on the earlier of the first anniversary of the June 5, 2026 grant date or immediately before the next annual meeting, subject to continued service. Settlement of the vested RSUs has been deferred under a prior deferral election.

Lin was also granted a stock option covering 16,667 shares of common stock at an exercise price of $21.23 per share. The option vests and becomes exercisable in full on the earlier of the first anniversary of the June 5, 2026 grant date or immediately before the next annual meeting of stockholders, contingent on continued board service through that date.

Arcutis Biotherapeutics director Howard G. Welgus received new equity awards as part of his board compensation. He acquired 5,778 Restricted Stock Units, each convertible into one share of common stock upon vesting, and a stock option for 16,667 shares at an exercise price of $21.23 per share.

The RSUs and option both vest 100% on the earlier of the first anniversary of the June 5, 2026 grant date or immediately before the next annual meeting of stockholders, subject to continued service. Following the RSU grant, he directly holds 38,378 shares of common stock.

Arcutis Biotherapeutics director Leonard Keith R reported equity awards connected to his service as a non-employee director as of the company’s 2026 annual meeting. He received 5,778 Restricted Stock Units (RSUs), each convertible into one share of common stock upon vesting on the earlier of the first anniversary of the June 5, 2026 grant date or immediately before the next annual meeting, subject to continued service. Settlement of the vested RSUs has been deferred under an RSU Deferral Election Form adopted on October 28, 2025. He was also granted a stock option for 16,667 shares of common stock at an exercise price of $21.23 per share, vesting on the same schedule and expiring on June 5, 2036. Following these awards, he holds 27,901 shares directly and 1,750 shares indirectly through the Leonard Family Trust dated August 28, 1996, for which he disclaims beneficial ownership except for his pecuniary interest.

Arcutis Biotherapeutics director Terrie Curran reported equity compensation grants. Curran received 5,778 Restricted Stock Units in connection with service as a non-employee director at the 2026 annual stockholder meeting, with one share of common stock issuable per RSU upon vesting. The RSUs vest on the earlier of the first anniversary of the June 5, 2026 grant date or immediately before the next annual meeting, subject to continued service, and settlement has been deferred under a prior RSU deferral election. Curran was also granted options covering 16,667 shares of common stock at a $21.23 exercise price, vesting 100% on the same schedule. Following these awards, Curran directly holds 23,526 common shares.

Arcutis Biotherapeutics, Inc. director Amit Munshi reported equity awards tied to his service as a non-employee director. He received 5,778 Restricted Stock Units that convert into an equal number of common shares when they vest. After this grant, he holds 9,799 common shares directly.

Munshi also received a stock option for 16,667 shares of common stock at an exercise price of $21.23 per share. Both the RSUs and the option vest 100% on the earlier of the first anniversary of the June 5, 2026 grant date or immediately before the next annual meeting of stockholders, subject to continued service through the vesting date.

Arcutis Biotherapeutics director Halley E. Gilbert reported equity awards rather than open-market trades. On June 5, 2026, Gilbert received 5,778 Restricted Stock Units (RSUs) in connection with service as a non-employee director. Each RSU will convert into one share of common stock when it vests.

The RSUs vest on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to continued service. On the same date, Gilbert was also granted a stock option for 16,667 shares of common stock at an exercise price of $21.23 per share, vesting on the same schedule. Following the RSU grant, Gilbert directly owns 27,901 shares of common stock.

Arcutis Biotherapeutics director Neha Krishnamohan received new equity awards, including restricted stock units and stock options. She was granted 5,778 RSUs and 16,667 stock options with a $21.23 exercise price per share. Both the RSUs and options vest 100% on the earlier of June 5, 2026 or immediately before the next annual stockholder meeting, subject to continued service. Following the grant, she holds 27,901 shares of common stock directly, plus the newly granted options for 16,667 underlying shares.

Arcutis Biotherapeutics, Inc. reported that SVP and Chief Financial Officer Latha Vairavan disposed of 435 shares of common stock at $21.05 per share. According to the footnote, the shares were sold to cover tax withholding obligations tied to vesting of Restricted Stock Units. Following this routine tax-related sale, Vairavan directly holds 85,978 common shares.

Arcutis Biotherapeutics, Inc. officer Patrick Burnett reported an open-market sale of 222 shares of common stock at $21.05 per share. According to the footnote, this sale was made solely to cover tax withholding obligations tied to the vesting of Restricted Stock Units. After the transaction, Burnett directly owned 120,244 shares, so the sale represents a very small portion of his holdings and reflects a compensation-related tax event rather than a discretionary reduction in his investment.

Arcutis Biotherapeutics, Inc. officer Masaru Matsuda reported selling 8,256 shares of common stock on May 4, 2026 in open-market transactions. The filing states these sales were made to cover tax withholding obligations arising from the vesting of Restricted Stock Units.

The transactions were executed under a Rule 10b5-1 trading plan adopted on June 5, 2025, with a plan end date of September 4, 2026. Shares were sold at weighted average prices of $23.6106 and $23.2696 per share across multiple trades within disclosed price ranges. Following the sales, Matsuda directly holds 126,689 shares of Arcutis common stock.

Arcutis Biotherapeutics insider files Form 4 for a small tax-related sale. Officer Patrick Burnett sold 684 shares of common stock on May 4, 2026 at a weighted average price of $23.6106 per share. The footnotes state the sale was made solely to cover tax withholding obligations from vesting Restricted Stock Units. After this transaction, Burnett directly holds 120,466 shares of Arcutis common stock.

Arcutis Biotherapeutics SVP and CFO Latha Vairavan disposed of 1,341 shares of Common Stock in a tax-related sale. The shares were sold on May 4, 2026 at a weighted average price of $23.6106 per share.

According to the disclosure, the sale was made to cover tax withholding obligations arising from the vesting of Restricted Stock Units, rather than as a discretionary portfolio trade. After this transaction, Vairavan directly holds 86,413 shares of Arcutis Biotherapeutics common stock.

The sale price reflects multiple trades executed in a range from $23.16 to $23.93 per share, with the weighted average reported in the filing.

Arcutis Biotherapeutics, Inc. director and officer Todd Watanabe reported an insider transaction involving company common stock. On May 4, 2026, he sold 3,172 shares at a weighted average price of $23.6106 per share. According to the filing, this sale was made to cover tax withholding obligations tied to the vesting of Restricted Stock Units, rather than a discretionary portfolio move.

Following the sale, Watanabe directly holds 720,755 common shares. The filing also lists additional indirect holdings through several trusts and an LLC, for which he is trustee or officer and where he disclaims beneficial ownership except for any pecuniary interest.

Arcutis Biotherapeutics director Howard G. Welgus sold shares of company stock in a planned transaction. On May 1, 2026, he completed an open-market sale of 7,144 shares of Arcutis common stock at a weighted average price of $22.9871 per share.

The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 11, 2025, which is scheduled to run through May 29, 2026. Following this transaction, Welgus directly holds 32,600 Arcutis common shares.

Arcutis Biotherapeutics director Howard G. Welgus reported an open-market sale of 10,000 shares of Common Stock at a weighted average price of $23.8801 per share. After this transaction, he directly holds 39,744 shares of Arcutis common stock.

The sale on April 1, 2026 was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 11, 2025, with a plan end date of May 29, 2026. The shares were sold in multiple trades at prices ranging from $23.61 to $24.12 per share.

Arcutis Biotherapeutics director Leonard Keith R reported a mix of stock option exercises and share sales in Arcutis Biotherapeutics, Inc. He exercised fully vested stock options for 27,052 and 12,220 shares of common stock at exercise prices of $8.63 and $7.51 per share, respectively, on March 2, 2026. On the same day, he sold 39,272 shares of common stock in open-market transactions at a weighted average price of $25.392 per share, under a Rule 10b5-1 trading plan adopted on November 18, 2025 with an end date of February 16, 2027. After these transactions, he directly owned 22,123 Arcutis shares and an additional 1,750 shares were held indirectly by the Leonard Family Trust, for which he is a trustee and disclaims beneficial ownership except for any pecuniary interest.

Arcutis Biotherapeutics director Howard G. Welgus sold 10,000 shares of common stock in an open-market transaction. The sale took place on March 2, 2026 at a weighted average price of $25.6518 per share, in multiple trades between $25.37 and $26.10. After this sale, he directly owned 49,744 shares. The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 11, 2025 with an end date of May 29, 2026.

Arcutis Biotherapeutics officer Larry Todd Edwards reported both stock sales and new equity awards. On March 2, 2026, he executed open-market sales totaling 3,687 shares of common stock at weighted average prices around the mid‑$20s per share to cover tax withholding obligations tied to vested restricted stock units.

On February 27, 2026, he received a grant of 77,000 stock options and a separate award of 30,000 restricted stock units, both at a reported price of $0.0000 per share. Following these transactions, his direct common stock holdings were reported at 175,178 shares, and the new options will vest monthly over four years starting March 1, 2026.

Arcutis Biotherapeutics director and officer Todd Watanabe reported a mix of stock sales and new equity awards. On March 2, 2026, he sold a total of 37,349 shares of common stock in open-market transactions at weighted average prices of $25.1606 and $25.9139 per share. A footnote states these shares were sold to cover tax withholding obligations related to vesting restricted stock units (RSUs).

On February 27, 2026, he received an option covering 266,000 shares, vesting monthly over four years starting March 1, 2026, and a grant of 102,000 RSUs, vesting 25% annually each March 1 beginning in 2027. The filing also notes additional shares held by several trusts and an LLC, for which he disclaims beneficial ownership beyond any pecuniary interest.

Arcutis Biotherapeutics executive Masaru Matsuda reported a mix of stock sales and equity awards. On March 2, 2026, he sold a total of 12,058 shares of common stock in open-market transactions at weighted average prices around $25–$26, under a Rule 10b5-1 trading plan ending on September 4, 2026. Some sales are described as covering tax withholding obligations from restricted stock unit vesting. Following these sales, he continued to hold over 130,000 shares directly.

On February 27, 2026, Matsuda received equity compensation, including 97,000 stock options and 37,000 restricted stock units. The options vest monthly over four years starting March 1, 2026, and the RSUs vest 25% annually each March 1 beginning in 2027, contingent on continued service to the company.

Arcutis Biotherapeutics, Inc. SVP and Chief Financial Officer Latha Vairavan reported both stock awards and small share sales. On February 27, 2026, she received grants of 27,000 Restricted Stock Units (RSUs), each convertible into one common share, vesting 25% annually starting March 1, 2027, and a stock option for 70,000 shares that vests monthly over four years from March 1, 2026.

On March 2, 2026, she sold a total of 2,853 common shares in open‑market transactions at weighted average prices of $25.1605 and $25.9140 per share, in price ranges disclosed in the footnotes, to cover tax‑withholding obligations upon RSU vesting. After these sales, she directly held 87,754 common shares.

Arcutis Biotherapeutics insider equity activity mixes sales and new awards. Officer Patrick Burnett sold 6,106 and 181 shares of common stock on March 2, 2026 at weighted average prices of $25.1604 and $25.9140. A footnote explains these sales were made to cover tax withholding obligations from vesting restricted stock units, rather than discretionary open‑market selling.

Burnett also received equity compensation on February 27, 2026, including a stock option grant for 77,000 shares and a 30,000‑share restricted stock unit award, both with no cash exercise or purchase price at grant. Another entry reflects 16,750 RSUs tied to an earlier performance grant whose milestone was certified on August 18, 2022. A separate footnote notes a prior reporting error that understated his beneficial ownership by 18 to 36 shares, now corrected.

Arcutis Biotherapeutics executive Masaru Matsuda reported multiple stock sales. On February 2, 2026, he sold blocks of Arcutis common stock at weighted average prices of $24.97 to $25.63, in several transactions disclosed in the filing.

The filing explains that one sale was made to cover tax withholding obligations tied to vesting restricted stock units granted on January 12, 2024. All reported transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on June 5, 2025. Following these trades, Matsuda beneficially owned 110,003 shares of Arcutis common stock in direct form as the company’s SVP, General Counsel and Corporate Secretary.

Arcutis Biotherapeutics executive Patrick Burnett, Executive Vice President and Chief Medical Officer, reported selling Arcutis common stock in two transactions. On February 2, 2026, he sold 3,675 shares at a weighted average price of $25.4984 to cover tax withholding tied to vesting restricted stock units. On February 4, 2026, he sold 9,794 shares at a weighted average price of $25.8064. Both transactions were executed under a Rule 10b5-1 trading plan adopted on December 12, 2024, with a plan end date of February 27, 2026. After these sales, Burnett directly beneficially owned 80,651 shares of Arcutis common stock.

Arcutis Biotherapeutics President and CEO Todd Watanabe, who also serves as a director, sold 19,833 shares of common stock on February 2, 2026 at a weighted average price of $25.4984 per share. The sale was made to cover tax withholding obligations arising from the vesting of previously granted restricted stock units.

After this transaction, Watanabe beneficially owned 721,306 common shares directly. Additional indirect holdings are reported through several entities, including trusts and an LLC, with reported positions of 25,410 shares, 25,410 shares, 57,358 shares, and 124,956 shares, where he disclaims beneficial ownership beyond his pecuniary interest.

Arcutis Biotherapeutics SVP CFO Latha Vairavan reported a small insider sale tied to equity compensation. On February 2, 2026, she sold 1,320 shares of common stock at a weighted average price of $25.4984 per share. According to the footnotes, the sale was made solely to cover tax withholding obligations arising from the vesting of previously granted restricted stock units. Following this transaction, she beneficially owns 63,607 shares of Arcutis common stock directly.

Arcutis Biotherapeutics director Howard G. Welgus sold shares under a pre-set trading plan. On February 2, 2026, he sold 10,000 shares of Arcutis common stock at a weighted average price of $25.0483 per share pursuant to a Rule 10b5-1 plan adopted on March 11, 2025. After this planned sale, he beneficially owns 59,744 shares of common stock directly.

Arcutis Biotherapeutics executive Larry Todd Edwards reported a small insider sale of common stock. On February 2, 2026, he sold 2,052 shares at a weighted average price of $25.4984 per share, solely to cover tax withholding obligations from vesting restricted stock units (RSUs).

The RSUs were granted on January 12, 2024 and vest 25% annually each February 1, beginning in 2025, subject to continued service. After this tax-related sale, Edwards beneficially owns 148,865 shares, including 724 shares purchased under the company’s Employee Stock Purchase Plan on November 30, 2025.

Arcutis Biotherapeutics, Inc. Executive Vice President and Chief Medical Officer Patrick Burnett reported a planned sale of company stock. On January 5, 2026, he sold 2,490 shares of Arcutis common stock at a weighted average price of $28.9822 per share under a Rule 10b5-1 trading plan adopted on December 12, 2024, with a plan end date of February 27, 2026. After this transaction, he beneficially owned 94,120 shares of Arcutis common stock directly.

Arcutis Biotherapeutics, Inc. director Howard G. Welgus reported selling 10,000 shares of common stock on 01/02/2026 at a weighted average price of $28.9606 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on March 11, 2025, with a plan end date of May 29, 2026.

After this planned sale, Welgus beneficially owned 69,744 shares of Arcutis common stock directly. The shares were sold in multiple transactions at prices ranging from $28.905 to $29.17 per share.

Arcutis Biotherapeutics Executive Vice President and Chief Medical Officer Patrick Burnett reported an option exercise and share sale in Arcutis Biotherapeutics, Inc. common stock. On 12/15/2025, he exercised a stock option for 11,500 shares at an exercise price of $3.64 per share, then sold 11,500 shares on the same date at a weighted average price of $28.9436 per share under transaction code S.

These trades were made pursuant to a Rule 10b5-1 trading plan adopted on 12/12/2024, with a plan end date of 02/27/2026. After the transactions, Burnett beneficially owned 98,307 shares of common stock directly and 143,750 stock options. The report also corrects a prior overstatement of his beneficial ownership by 18 shares due to a scrivener's error.

Arcutis Biotherapeutics (ARQT) director Sue-Jean Lin reported stock option exercises and a share sale. On 11/24/2025, Lin exercised options to acquire 18,052 shares of common stock at an exercise price of $8.63 per share and another 7,220 shares at $7.51 per share. That same day, Lin sold 25,272 shares of common stock at a weighted average price of $30.7833 per share, in multiple trades between $30.56 and $30.91. After these transactions, Lin directly beneficially owned 26,735 shares of Arcutis common stock, along with remaining stock options for 9,000 shares and 5,000 shares that are exercisable into common stock.

Arcutis Biotherapeutics (ARQT) insider Todd Franklin Watanabe, the company’s President, Chief Executive Officer and a director, reported open-market sales of common stock on a Form 4. On November 21, 2025, he sold 1,055 shares of common stock at a price of $30.00 per share. On November 24, 2025, he sold an additional 48,945 shares at a weighted average price of $30.3556 per share.

The filing states these transactions were made under a Rule 10b5-1 trading plan adopted on June 3, 2025, with a plan end date of September 30, 2026. Following the reported sales, Watanabe beneficially owns 740,537 shares of Arcutis common stock directly, plus additional indirect holdings through several trusts and an LLC, for which he disclaims full beneficial ownership except to the extent of his economic interest.

Arcutis Biotherapeutics (ARQT) executive Masaru Matsuda, an officer serving as SVP General Counsel and Corporate Secretary, reported sales of company stock in a Form 4 filing. On 11/19/2025, he sold 989 shares of common stock at a weighted average price of $27.9541 and 1,561 shares at a weighted average price of $28.5. The sales were made to cover tax withholding obligations related to the vesting of Restricted Stock Units, rather than as discretionary open-market sales. After these transactions, Matsuda beneficially owned 151,476 shares of Arcutis common stock, held directly.

Arcutis Biotherapeutics (ARQT) director Halley E. Gilbert reported an option exercise and share sale. On 11/20/2025, Gilbert exercised a stock option to buy 12,220 shares of common stock at an exercise price of $7.51 per share. The underlying option had vested 100% on the first anniversary of May 31, 2023, subject to continuous service as a non-employee director.

On the same date, Gilbert sold 16,532 shares of common stock in open-market transactions at a weighted average price of $27.5491 per share, with individual trades ranging from $27.32 to $27.72. Following these transactions, Gilbert directly beneficially owned 22,123 shares of Arcutis Biotherapeutics common stock, and held no remaining derivative securities from this reported option.

Arcutis Biotherapeutics (ARQT) director Neha Krishnamohan reported option exercises and share sales. On 11/13/2025, she exercised stock options to acquire 27,052 shares at $8.63 and 12,220 shares at $7.51 per share, then sold 39,272 shares at a weighted average price of $23.1896 and an additional 1,232 shares at $23.37.

After these transactions, she directly owned 22,123 shares of Arcutis common stock. The filing notes that these trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on August 14, 2025, with an end date of November 2, 2026, which is designed to allow insiders to sell shares according to a preset schedule.